Potential KRAZATI® NSCLC patient wearing a colorful top and black and white striped jacket with a blue background.

In KRAS G12C-positive advanced NSCLC
This is my non-small
REVOLUTION

Focusing on yourself is your boldest move yet. Partnering with your care team and experiencing KRAZATI® (adagrasib)—an oral, targeted therapy—can keep the focus on you and your NSCLC.

 

KRAZATI doesn’t require a break in treatment before starting, which means you can continue fighting your cancer immediately after your first-line therapy ends, without a gap in treatment.*

 

*Based on the KRAZATI Prescribing Information; however, in the study, patients took a 2-week break after their most recent cancer treatment, including immunotherapy.

Sign up for information on KRAZATI  ❯

 

Actor portrayal.

HAVE YOU HAD
A BIOMARKER TEST?

RESOURCES DESIGNED FOR YOU

THE KRAZATI EXPERIENCE

Actor portrayals.
NSCLC=non-small cell lung cancer.



1914-US-2500108  12/25